LACTIC FERMENT COMPRISING A PARTICULAR STRAIN OF LACTOBACILLUS ACIDOPHILUS AND USE THEREOF

Abstract: The purified strain of Lactobacillus acidophilus CNCM/I-1492 (L.a. 1492) when administered alone or in combination with another Lactobacillus acidophilus (L.a.) strain and Lactobacillus casei (L.c.) strain, has a beneficial effect on the cholesterol blood level in mammals. It also strenghtens the immune system, facilitates the absorption of nutrients and stimulates the intestinal flora. Such strains also neutralize side effects caused by antibiotics. The invention concerns the specific strain L.a. I-1492, a ferment comprising L.a. I-1492, L.a. and L.c. strains, a dairy product obtained by this ferment and a method of manufacturing the dairy product.

Description: LACTIC FERMENT COMPRISING A PARTICULAR STRAIN OF LACTOBACILLUS ACIDOPHILUS AND USE THEREOF FIELD OF THE INVENTION The present invention concerns a purified strain Lactobacillus acidophilus identified as CNCM/l-1 492 (hereinafter called L.a. 1- 1 492), the microorganism from this strain, a lactic ferment comprising this strain, a process for making dairy products using this ferment, and the dairy products obtained by this process and containing at least 500 million per gram of Lactobacillus acidophilus (including the L.a. 1-1 492 strain) or 380 million/gram of L.a. 1-1492. The invention also concerns the use of a ferment comprising the strain Lactobacillus acidophilus CNCM/l-1 492 and of a dairy product containing the same in the pharmaceutical field for reducing the level of cholesterol in the blood of a mammal. BACKGROUND Yogurts are fermented dairy products obtained by fermentation of different lactic bacterias with milk. The most widely used milk is cow's milk. These lactic bacterias (mainly Streptococcus thermophilus and Lactobacillus bulgaricus) are foreign bodies to the human intestinal flora and are not implanted in the digestive system during consumption of these dairy products. Other lactic bacterias are present in their natural state in the human digestive system. It seems that the presence of such bacterias are beneficial and helpful in particular to improve the absorption of food while maintaining the equilibrium in the intestinal flora. Such other bacterias in particular are Lactobacillus casei and Lactobacillus acidophilus. The dairy products containing such bacterias are of particular interest inasmuch as they allow better digestion and provide an easier absorption of calcium when the latter is in the presence of moderate amounts of lactose. Indeed, during fermentation, milk protein and sugar are hydrolyzed, thereby falicitating hydrolisation of minerals such as calcium, iron essential to their absorption. It has also been demonstrated that the ingestion of a fermented milk containing Lb Acidophilus alone increase the phagocytes activities thereby stimulating non specific defense of the host. Furthermore, the consumption of fermented milk Lb casei and milk Lb acidophilus has been found effective to rapidly reduce acute diarrhea in humans. Lb acidophilus has also been found to have a healing effect on other gastric- intestinal related problems such as diverticulitis, food poisining, abnormal fermentation. However, perfecting such products is extremely difficult inasmuch as these bacterias naturally present in humans are not easily given to rapid production of dairy products having a pleasant taste and texture. Furthermore, it is known that the performance of combined strains in a same ferment is unpredictable because of the interactions between the strains. Hence the performance and properties of a ferment can be significantly different from the performance and properties of the pure strains of which the ferment is composed. It has now been, surprisingly, discovered that the Lactobacillus acidophilus I- 1492 strain, or L.a. 1-1492, has not only a beneficial effect on digestion and the equilibrium of the intestinal tract, but also has a major pharmaceutical effect allowing the reduction of the cholesterol level in the blood of mammals, and more particularly humans. This effect is particularly remarkable when the strain L.a. 1-1492 is combined with some lactic bacterias in a lactic ferment. A thorough study of these products has revealed, in a totally surprising and unexpected way, that fermented dairy products obtained from such ferment display therapeutic properties which reduce the amount of cholesterol in the blood. The main factor seems to evidently be due to the presence of a high concentration of the strain L.a. 1-1 492 since such an effect has not been established for other yogurts and/or lactic bacterias. The combination of lactic bacterias which compose the ferment according to the invention, allows an increase and acceleration of the development of the strain L.a. 1-1492 during production of the fermented dairy product. Furthermore, it is very likely that this ferment creates a synergy and thereby achieves the production of a fermented dairy product having improved therapeutic results as compared to the dairy products obtained with the L.a. 1-1492 strain alone. BRIEF DESCRIPTION OF THE INVENTION The present invention concerns a purified strain Lactobacillus acidophilus 1-1492 (L.a. 1-1492) and the microorganism from this strain. This strain can used in a lactic ferment, which is also an object of the invention, comprising a mixture of the following lactic strains: - L.a. 1- 1492 - at least one other Lactobacillus acidophilus strain; and - at least one Lactobacillus casei strain. The latter two strains may be of commercial origin and can be purchased from manufacturers of lactic ferments. For example, the commercial Lactobacillus acidophilus strain that is used in the ferment of the present invention may be the one sold under the trademark RP Texel by Rhδne-Poulenc or the one sold under the trademark L.a. RO-52 by Rosell. The commercial Lactobacillus casei strain may be the one sold under the trademark E2AL by Rhδne-Poulenc. Another object of the invention is a fermented lactic product of the yogurt type obtained by fermentation of the strain or of the lactic ferment according to the invention, with a dairy compound. A further object of the invention is a method of manufacturing a fermented dairy product by the fermentation of the ferment according to the invention, said product having the texture of a yogurt. A further object of the invention is the use of such fermented dairy product in the stimulation of the immune system for curing sore throat, flu, sinusitis and urinary infection. This same fermented dairy product has also been found to be useful in treating gatric-intestinal related diseases and infections. Still a further object of the invention is the use of the above dairy products to reduce the cholesterol blood level in mammals, especially humans, and a method of medical treatment comprising the ingestion of a dairy product according to the invention. The invention as well as its advantages will be better understood upon reading the following non-restrictive description, and by referring to the enclosed drawings. DETAILED DESCRIPTION OF THE INVENTION The purified Lactobacillus acidophilus strain 1-1492 according to the invention was filed on November 1 5, 1 994 in the National Collection of Microorganism Cultures (25, Rue du Dr. ROUX, F-75724 Paris Cedex 1 5) according to the provisions of the Budapest Treaty. The physiological, chemical and biochemical characteristics of the acidophilus strains that may be used in the ferment according to the invention are shown in tables 1 and 2. It has been found that the L.a. 1-1 492 strain present chemical, biochemical and physiological characteristics similar to those of the other L.a. strains. As a matter of fact, the L.a. 1-1492 strain differs from the others only in that it degrades cholesterol more efficiently. Table 1 Lactobacillus type (Group I); physiological characteristics Table 2 Lactobacillus type (Group I): chemical and biochemical characteristics The fermenting profile for the L.a. strains which include the L.a. 1-1 492 strain is shown in table 3. o — __ _ E n ω C rH x 3 O ro o H u ϊ -Q O o Table 3 (continued) Lactobacillus type (Group I): fermenting profile The chemical, biochemical and physiological characteristics of the casei strain which can be used in the ferment according to the invention in combination with the L.a. 1-1492 strain, are compiled in tables 4 and 5. Table 4 Lactobacillus type (Groupe II) Chemical and biochemical characteristics Table 5 Lactobacillus type (Group I I): physiological characteristics o o- o 5 O QJ o c f0 0) S σ i-- 11. 5 " 2 S 3 a ϋ σ» • o o • 9 θ|qει UJ UMoqs SJ UJBJJS IΘSBO 9tμ jo θμ ojd βu uθiujθj aiy. qe LZL£W6 OΛV SI600//.6VD/X3J Table 6 (continued) Lactobacillus type (Group II): fermenting profile 9d A dairy product according to the present invention can be obtained by fermenting the ferment of the invention in a milk-based medium. For this purpose, the following process may be used. Firstly, the L.a. 1-1 492, acidophilus and casei strains are incubated in a MRS type fermentation medium under 10% of CO2 according to a standard program comprising several steps. The recombined lacteal base which is partially lactose-free and degassed is pasteurized for 1 ,5 minutes at 95 °C and inoculated at 1 0% . Finally, it is incubated according to the following program: 1 ) the L.a.1- 1492 strain: 2 hours at 37 °C under 1 0% CO 2 ; 2) the acidophilus strain: 2 hours at 37 °C; and 3) the casei strain: 1 hour at 37 °C. The product is then co-fermented in an anaerobic atmosphere and medium for 1 5 hours at 37 °C (degassing under CO2) . In order to realize the invention, any acidophilus and casei strains may be used as long as they present no health risk. Preferably, the following acidophilus strain should be used: RP Texel ™ by Rhδne-Poulenc and L.a. RO-52 ™by Rosell. The commercial casei E2AL™ by Rhόne-Poulenc is preferably used. The 10 proportions of L.a. 1-1 492, acidophilus and casei cultured strains, are respectively about 70/20/10. These proportions may evidently be somewhat varied. Nevertheless, the total concentration of Lactobacilli acidophilus (including those obtained from L.a.1-1 492 strains) which is present in the dairy product once fermented, must be at least equal to 500* 1 0"/g and the concentration of L.a. 1-1492 must be at least 380* 10 6 /g. Although total amino acid content is similar to milk, free amino acid are significantly higher. The level of peptides comprised in the fermented dairy product, having a molecular weight between 1000 and 5000 Da. is around 30% and the level of small peptides having less than 1 0 residues is approximately 1 5% . It is known that such levels of peptides fortify, in a suprising way, the immune and digestive systems. In the fermented dairy product thus obtained, the dairy proteins are disintegrated into peptides whose size may be more or less large, allowing for an easier digestion of the product. Indeed, subject allergic to milk proteins were able to digest the fermented dairy product thus obtained. Once the fermented dairy product is manufactured, it is thereafter refrigerated and must be consumed before it deteriorates. Generally, the consumption of the same must take place within a period of 60 to 1 20 days. A dairy product according to the invention has been commercialized by the applicant Bio-K PLUS International Inc. (whose address is: 635 Victoria, Westmount, H3Y 2R9, CANADA) since June 2, 1 996, under the trade-mark BioK + . However, the ferment of the present invention, which comprises the L.a. 1-1492, acidophilus and casei strains has never been disclosed. Nor have the specific purified strain L.a. 1-1 492 and method of manufacturing the commercialized Bio K + product been disclosed. As it may be appreciated, a man skilled in the art would not , with the commercialized Bio K + product at hand, be able to reproduce the same product. 11 The applicant has also suprisingly found that the fermented dairy product according to the invention has a stimulation effect on the immune system and is thereby effective for treating various inflammatory reactions and/or infectious diseases such as colds, sinusitis, urinary infections. The recommanded treatment is a dose of 1 00g per day of the fermented dairy product for a period of 10 to 60 days depending on the case. Furthermore the fermented dairy product neutralizes side effects caused by antibiotics. The fermented dairy product of the invention has also been found to have significant effect in treating diseases and infections related to the intestinal tract such as diarrhea, diverticulitis, mega-colon, Crohn disease. Indeed, the applicant has found that daily consumption of the dairy product of the invention eliminates most cases of the above-mentioned diseases. Furthermore, the fermented dairy product of the present invention contains a fair amount of folic acid and vitamin B1 2 which was produced during fermentation of the lactic culture. As a result, consumption of such product resulted in fast recuperation time in subjects whom regularly exercise. This observation is especially true for older individuals. As a matter of fact, 8 out of 10 people consuming the product on a daily basis said they felt better. The fermented dairy product according to the invention may also be used for the treatment of high blood levels of cholesterol. The recommended treatment consists of a dose of 100g per day for a period of 30 to 60 days. The effect of this dairy product on the level of cholesterol in the blood was tested on a group of 14 patients to whom was prescribed a dose of 100g per day for a period of, depending on the case, 30 to 60 days. The results of these tests are shown in the following charts where the total cholesterol blood level (CHO total) present in the blood is indicated. Hence, these tests reveal that upon 12 regular intake during a period of 60 days, the total cholesterol level failed from between 7 to 22% and that the "low density level" (LDL) failed from between 9 to 25%. Furthermore, the level of triglycerides (TRIQLY) drops from between 28 to 43% . It can be seen that after 60 days of treatment, certain individuals recover a normal level of CHO/HDL (High density level) ratio, that is, a level comprised between 3.2 to 4.4 or of LDL/HDL ratio (that is, inferior to 3.8 for people aged 30 and over). Of course, the above-mentioned example is solely for the purpose of illustrating the invention and is given only as a representative means. It must not be used to limit the scope of the invention which may extend to any obvious variations. For example, one may consider administering the ferment of the invention or powder on a dehydrated support. BIOK + CHOLESTEROL STUDY RD Case HI (Med) T = 0 T = 30 T - 60 REDUCTION CHO TOTAL 6,64 6,06 5, 16 22% after 60 days HDL 0,72 0,62 0,66 LDL not available TRIGLY 4,64 6,64 4,59 CHO/HDL 9,22 9,77 7,82 LDL/HDL not available 13 RM Case #2 (Med) T = 0 T = 30 T = 60 REDUCTION CHO TOTAL 5,90 5,05 4,65 21% after 60 days HDL 1,36 1,44 1,14 LDL 4,13 3,25 3,09 25% after 60 days TRIGLY 0,91 0,80 0,93 CHO/HDL 4,33 4,43 4,07 LDL/HDL 3 2,3 2,7 EC Case #3 (Med) T = 0 T = 30 REDUCTION CHO TOTAL 7,94 6,49 18% after 30 days HDL 0,98 0,84 LDL 5,86 4,88 17 % after 30 days TRIGLY 2,41 1,70 29% after 30 days CHO/HDL 8,10 7,72 LDL/HDL 6 5,8 MB Case #4 (Med) T-0 T = 30 T = 60 REDUCTION CHO TOTAL 7,75 6,49 6,58 15% after 60 days HDL 1,15 1,00 1,06 LDL 6,05 4,89 5,00 17% after 60 days TRIGLY 1,22 1,31 1,15 CHO/HDL 6,74 6,49 6,20 LDL/HDL 5,3 4,9 4,7 14 IM Case #5 (Med) T = 0 T = 30 T = 60 REDUCTION CHO TOTAL 7,06 6,74 6,59 6,7% after 60 days HDL 1,26 1,29 1,16 LDL 5,08 4,70 4,56 10% after 60 days TRIGLY 1,59 1,65 1,92 CHO/HDL LDL/HDL 3,6 3,9 YC Case #6 (Med) T = 0 T = 30 T = 60 REDUCTION CHO TOTAL 7,38 7,03 7,06 4,3% after 60 days HDL 1,49 1,65 1,66 LDL 5,45 4,84 4,91 11.2% after 30 days TRIGLY 0,97 1,18 1,07 CHO/HDL LDL/HDL 3,7 2,9 3,0 19% after 60 days ES Case HI (Med) T = 0 T = 30 T = 60 REDUCTION CHO TOTAL 6,33 6,11 6,16 2,7% after 60 days HDL 1,26 1,04 1,08 LDL 4,24 4,24 4,48 TRIGLY 1,83 1,83 1,31 28,4% after 60 days CHO/HDL LDL/HDL 3,4 4,1 4,2 15 RL Case #8 (Med) T = 0 T = 30 T = 60 REDUCTION CHO TOTAL 6,41 6,64 6,84 6,7% after 60 days HDL 1,28 1,30 1,13 LDL 4,73 4,85 5,02 TRIGLY 0,88 1,07 1,52 CHO/HDL LDL/HDL 3,7 3,7 4,4 JGT Case #9 (Med) T = 0 T = 30 REDUCTION CHO TOTAL 6,33 6,36 HDL 1,88 1,90 LDL 4,07 3,93 TRIGLY 0,84 1,16 CHO/HDL LDL/HDL 2,2 2,1 TB CC Case If 10 (Med) T = 0 T = 60 REDUCTION CHO TOTAL 7,64 6,99 HDL 0,96 1,03 LDL 5,18 5,10 TRIGLY 3,31 1,89 43% after 60 days CHO/HDL 7,9 6,8 LDL/HDL 5,4 5,0 16 XB Case #11 (Med) T = 0 T = 30 REDUCTION CHO TOTAL 7,03 6,31 10% after 30 days HDL 1,23 1,18 LDL 4,97 4,45 10,5% after 30 days TRIGLY CHO/HDL 5,7 5,3 LDL/HDL 4,04 3,77 Return to normal XX Case #12 (Med) T = 0 T = 30 T = 60 REDUCTION CHO TOTAL 6,84 6,25 6,03 12% after 60 days HDL 1,21 1,17 1,13 LDL 4,93 4,38 4,44 9% after 60 days TRIGLY CHO/HDL LDL/HDL 4,07 3,74 3,93 CV Case #13 (MR) T = 0 T=120 days REDUCTION CHO TOTAL 6,60 5,18 21 % after 4 months HDL 1,28 1,30 LDL 3,51 2,79 20,5% NORMAL TRIGLY 3,96 2,39 39% CHO/HDL 5,12 3,98 22% return to NORMAL LDL/HDL 2,74 2,14 22% return to NORMAL 17 ITC Case #14 (HCLM) τ=o T = 30 T = 60 REDUCTION CHO TOTAL 9,41 8,34 7,76 17,5% HDL 1,27 1,11 1,10 LDL 7,35 6,31 5,89 20% TRIGLY 2,13 2,48 1,68 21 % return to NORMAL CHO/HDL 7,4 7,5 7,05 LDL/HDL 5,78 5,68 5,4 HCLM Charles Le Moine Hospital MED Medicis REFERENCES CHO TOTAL 4,2-5, HDL 0-0,9 LDL < 3,4 TRIGLY 0,4- 2, 1 CHO/HDL 3,2-4,4 LDL/HDL < 3,8 for > 30 years old.

Claims: 18 CLAIMS: 1 . The microorganism Lactobacillus acidophilus CNCM 1-1 492. 2. A biologically pure culture of the microorganism Lactobacillus acidophilus CNCM 1-1 492. 3. A lactic ferment comprising a purified strain of Lactobacillus acidophilus CNCM 1-1 492. 4. A lactic ferment of claim 3, further comprising at least one other Lactobacillus acidophilus strain and at least one Lactobacillus casei strain. 5. A method for producing a fermented dairy product by fermentation of the ferment of claim 4 in a milk-based medium. 6. A fermented dairy product obtained by the method of claim 5, wherein it comprises at least 500 millions per gram of microorganisms of the Lactobacillus acidophilus strain, where at least 380 millions per gram are microorganisms of the Lactobacillus acidophilus CNCM/l-1 492 strain. 7. A method for reducing blood cholesterol level in a mammal, comprising the step of administrating through ingestion 1 00 gram per day of the fermented dairy product as claimed in claim 6, for a period of 30 to 60 days. 8. A method for treating infectious diseases, comprising the step of administrating through ingestion 1 00 gram per day of the fermented dairy product as claimed in claim 6, for a period of 10 to 60 days. 9. A method of claim 8, wherein the infectious diseases consist of colds, sinusitis and urinary infections. 19 1 0. A method for treating gastric-intestinal related diseases and infections comprising the step of administering through ingestion 100 gram per day of the fermented dairy product of claim 6 for a minimum period of 1 0 to 60 days. 1 1 . A method of claim 10, wherein the gastric-intestinal diseases and infections consist of food poisining, diarrhea, diverticulitis, mega-colon and Crohn disease. 1 2. Use of the fermented dairy product of claim 6, for reducing blood cholesterol level in a mammal. 1 3. Use of the lactic ferment of claim 4, for reducing blood cholesterol level in a mammal. 1 4. Use of the Lactobacilus acidophilus CNCM 1-1 492 of claim 2, for reducing the blood cholesterol level in a mammal. 1 5. Use of the fermented dairy product of claim 6, for treating infectious diseases comprising colds, sinusitis and urinary infections 1 6. Use of the lactic ferment of claim 4, for treating infectious diseases comprising colds, sinusitis and urinary infections. 1 7. Use of the Lactobacilus acidophilus CNCM 1-1492 of claim 2, for treating infectious diseases comprising colds, sinusitis and urinary infections. 1 8. Use of the fermented dairy product of claim 6, for treating gastric-intestinal related diseases and infections comprising diarrhea, diverticulitis, mega-colon and Crohn disease. 20 1 9. Use of the fermented dairy product of claim 4, for treating gastric-intestinal related diseases and infections comprising diarrhea, diverticulitis, mega-colon and Crohn disease. 20. Use of the fermented dairy product of claim 2, for treating gastric-intestinal related diseases and infections comprising diarrhea, diverticulitis, mega-colon and Crohn disease. 21 . Use of the feremented dairy product of claim 6 for neutralizing side effects caused by antibiotics.

Inventors: LUQUET FRANCOIS-MARIE, LUQUET, FRANCOIS-MARIE
Applicants: BIO K & INTERNATIONAL INC, LUQUET FRANCOIS MARIE, BIO K + INTERNATIONAL INC., LUQUET, FRANCOIS-MARIE
Application year: 1997
Main classification: C12N1
IPC codes: A23C9, A61K35, C12N1